Kurt R. Karst provides regulatory counsel to pharmaceutical manufacturers on Hatch-Waxman patent and exclusivity, drug development, pediatric testing, and orphan drugs, including lifecycle management, approval, post-marketing, and exclusivity issues. He is co-founder and primary author of HPM's FDA Law Blog, co-author of Generic and Innovator Drugs: A Guide to FDA Approval Requirements, and has authored several articles.